BriaCell Therapeutics 

BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company, which engages in the development of immunotherapies for treatment of cancer. Its technologies include Bria-IMT and Bria-OTS. The company was founded by Charles L. Wiseman and Isaac B. Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.

Earnings data Q2 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the development of novel immunotherapies to transform cancer care. It currently advancing its Bria-IMT™ targeted immunotherapy in combination with an immune check point inhibitor in a pivotal 1 Phase 3 study in metastatic breast cancer. The company was founded by Charles L. Wiseman and Isaac Benjamin Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.

PHILADELPHIA and VANCOUVER, British Columbia, Oct. 18, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that BriaCell will be presenting at the following two upcoming scientific conferences.

BriaCell Announces Presentations at the 2023 Society for the Immunotherapy of Cancer (SITC) and San Antonio Breast Cancer (SABC) Conferences

PHILADELPHIA and VANCOUVER, British Columbia, Oct. 11, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announces that it will host a virtual KOL event on Bria-IMT™ potential in advanced metastatic breast cancer on Thursday, October 26, 2023 at 10:00am ET. To register for the event, please click here.

BriaCell To Host Virtual Key Opinion Leader Event on Bria-IMT™ Potential in Advanced Metastatic Breast Cancer on October 26, 2023 Featuring Dr. Adam M. Brufsky from University of Pittsburgh School of Medicine and Dr. Saranya Chumsri from Mayo Clinic

PHILADELPHIA, Pa. and VANCOUVER, British Columbia, Oct. 04, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce a partnership with New York Cancer & Blood Specialists (NYCBS), a group of leading community cancer centers in the United States, to evaluate the Bria-IMT™ combination with a checkpoint inhibitor in its pivotal Phase 3 registration study in advanced breast cancer patients in New York.

BriaCell Partners with New York Cancer & Blood Specialists (NYCBS) for Pivotal Phase 3 Study of Bria-IMT™ in Advanced Breast Cancer

PHILADELPHIA and VANCOUVER, British Columbia, Oct. 03, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announces that its registration-enabling pivotal Phase 3 study of its lead clinical candidate, Bria-IMT™, in combination with an immune check point inhibitor, is fully approved by the Institutional Review Board (IRB) and will soon enroll patients with advanced metastatic breast cancer.

BriaCell Initiates Pivotal Phase 3 Study of Bria-IMT™ in Advanced Metastatic Breast Cancer

PHILADELPHIA and VANCOUVER, British Columbia, Sept. 08, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announces the completion of patient enrollment in its Phase 2 clinical study and reports clinical data showing strong patient survival benefit and clinical benefit in advanced metastatic breast cancer patients.

BriaCell Reports Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast Cancer

TORONTO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announces that the Company has closed the previously announced plan of arrangement spinout transaction (the "Arrangement") pursuant to which certain pipeline assets of the Company, including Bria-TILsRx™ and protein kinase C delta (PKCδ) inhibitors for multiple indications including cancer (the "SpinCo Assets"), were spun-out to BriaPro Therapeutics Corp. ("SpinCo"), resulting in a 2/3rd owned subsidiary of the Company with the remaining 1/3rd held by BriaCell shareholders ("BriaCell Shareholders").

BriaCell Therapeutics Corp. Announces Closing of Plan of Arrangement Spinning Out BriaPro Therapeutics Corp. to Existing Shareholders

PHILADELPHIA and VANCOUVER, British Columbia, Aug. 31, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that it has accepted a letter of intent from Dr. Massimo Cristofanilli, Director of Breast Medical Oncology and Associate Director of Precision Medicine in the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, outlining the parties' plans and commitment, upon regulatory approval, to initiate a Phase 2 investigator-initiated clinical study to evaluate BriaCell's novel immunotherapy, Bria-IMT™, in combination with a check point inhibitor (CPI), in early stage, newly diagnosed, high-risk triple negative breast cancer (TNBC) patients in the neoadjuvant setting.

BriaCell Accepts Letter of Intent from Weill Cornell Medicine Outlining Plans to Initiate a Clinical Trial of Bria-IMT™ in High-Risk Early-Stage Triple Negative Breast Cancer

PHILADELPHIA and VANCOUVER, British Columbia, Aug. 25, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announces that the Company has received court approval for the previously-announced plan of arrangement (the "Arrangement") pursuant to which certain pipeline assets of the Company, including Bria-TILsRx™ and protein kinase C delta (PKCδ) inhibitors for multiple indications including cancer (the "SpinCo Assets"), will be spun-out to BriaPro Therapeutics Corp. ("SpinCo"), resulting in a 2/3 owned subsidiary of the Company upon closing of the Arrangement with the remaining 1/3 held by BriaCell shareholders ("BriaCell Shareholders").

BriaCell Receives Court Approval for the Share Arrangement Spinning Out BriaPro Therapeutics (SpinCo) to Existing Shareholders

PHILADELPHIA and VANCOUVER, British Columbia, Aug. 18, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (TSX: BCT, Nasdaq: BCTX, BCTXW) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that at a special meeting held today (the "Meeting"), shareholders of BriaCell ("BriaCell Shareholders") approved a special resolution (the "Arrangement Resolution") approving the previously-announced plan of arrangement (the "Arrangement") pursuant to which certain pipeline assets of the Company, including Bria-TILsRx™ and protein kinase C delta (PKCδ) inhibitors for multiple indications including cancer (the "SpinCo Assets"), will be spun-out to BriaPro Therapeutics Corp. ("SpinCo"), resulting in a 2/3 owned subsidiary of the Company upon closing of the Arrangement with the remaining 1/3 held by BriaCell shareholders. In addition, BriaCell Shareholders also approved the adoption of a rolling 15% stock option plan of SpinCo (the "SpinCo Option Plan Resolution") and the grant of certain stock options granted by BriaCell in August 2022 (the "Option Issuance Resolution" and, together with the Spinco Option Plan Resolution and the Arrangement Resolution, the “Resolutions”), all as further described in the proxy statement of the Company dated July 24, 2023 (the "Proxy Statement").

BriaCell Therapeutics Corp. Announces Voting Results From Special Meeting

PHILADELPHIA and VANCOUVER, British Columbia, Aug. 16, 2023 (GLOBE NEWSWIRE) --  BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that the National Cancer Institute (NCI), the United States federal government's principal agency for cancer research and training, has awarded the Company a research grant to advance its platform of personalized off-the-shelf immunotherapies for cancer.

BriaCell Awarded National Cancer Institute Grant to Advance its Bria-OTS™ Immunotherapy for Cancer

PHILADELPHIA and VANCOUVER, British Columbia, June 27, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage immunotherapy company driven to fight cancer and improve patients' lives, announces that it has received approval from FDA on its pivotal registrational study design for Bria-IMT™ in combination with a checkpoint inhibitor in advanced metastatic breast cancer.

FDA Approves BriaCell's Pivotal Registrational Study Design in Advanced Metastatic Breast Cancer

PHILADELPHIA and VANCOUVER, British Columbia, May 25, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is pleased to announce that it has entered into an arrangement agreement dated May 24, 2023 with BriaPro Therapeutics Corp. (“SpinCo”), a wholly-owned subsidiary of the Company (the “Arrangement Agreement”) pursuant to which certain pre-clinical pipeline assets of the Company, including Bria-TILsRx™ and protein kinase C delta (PKCδ) inhibitors for multiple indications including cancer (the “SpinCo Assets”), will be spun-out to SpinCo by way of a court approved statutory plan of arrangement under the Business Corporations Act (British Columbia) (the “Arrangement”).

BriaCell Enters Definitive Arrangement Agreement for the Spin Out of BriaPro Therapeutics Corp.

PHILADELPHIA and VANCOUVER, British Columbia, May 19, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is pleased to announce that the Company has completed the previously-announced strategic investment by Prevail Partners, LLC (“Prevail Partners”) in the Company (the “Investment”), in accordance with a stock purchase agreement (the “Agreement”) entered into between the Company and Prevail Partners on May 12, 2023. Pursuant to the Agreement, the Company issued 463,408 common shares (the “Shares”) to Prevail Partners (the “Issuance”) at a price per Share of US$8.63 for aggregate gross proceeds of US$4 million.

BriaCell Closes $4 Million Strategic Investment by Prevail Partners, LLC at US$8.63 per Share

PHILADELPHIA and VANCOUVER, British Columbia, May 15, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, announces that the Company has signed a Master Service and Technology Agreement (“MSTA”) agreement with Prevail InfoWorks, Inc. (“InfoWorks”), a Philadelphia, PA based Contract Research Organization (CRO), to provide clinical services and technologies for BriaCell's upcoming pivotal study in advanced metastatic breast cancer. Services include clinical site coordination, project management, clinical monitoring and pharmacovigilance (safety management) services, and the use of InfoWork's integrated real-time data analytics platform, The Single Interface®, for clinical support and real-time data analysis.

BriaCell Announces $4 Million Strategic Investment and Clinical Alliance with Prevail Partners, LLC and Prevail InfoWorks, Inc.

PHILADELPHIA and VANCOUVER, British Columbia, April 17, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is presenting positive clinical data from its lead product candidate, Bria-IMT™, summarized in four poster sessions during the 2023 American Association for Cancer Research (AACR) Annual Meeting held from April 14 – 19, 2023 at Orange County Convention Center, Orlando, Florida.

BriaCell Presents Positive Data Demonstrating Survival and Clinical Benefits in Advanced Metastatic Breast Cancer at the 2023 AACR

PHILADELPHIA and VANCOUVER, British Columbia, March 30, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, announces today that its Board of Directors has unanimously approved a potential reorganization (the “Transaction”) that would result in the spin-out of certain pre-clinical pipeline assets of the Company, specifically Bria-TILsRx™, and PKCδ inhibitors for multiple indications including cancer (collectively, the “SpinCo Assets”) to an unlisted corporation to own the SpinCo Assets (“SpinCo”). On closing of the Transaction, it is anticipated that the SpinCo Assets will be majority-owned, controlled, and governed by BriaCell and owned by BriaCell shareholders of record who will receive SpinCo Shares as defined herein.

BriaCell Announces Intention to Spin-Out Certain Pre-Clinical Assets into a Newly Created “SpinCo” Entity whereby Shareholders to Receive One New Share of “SpinCo” in Addition to Each Current Share of BriaCell Already Held

PHILADELPHIA and VANCOUVER, British Columbia, March 15, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, has been selected to present four posters at the 2023 American Association for Cancer Research (AACR) Annual Meeting held from April 14 - 19, 2023 at Orange County Convention Center, Orlando, Florida.

BriaCell to Present Clinical and Survival Data in Advanced Metastatic Breast Cancer at the 2023 AACR Annual Meeting

BriaCell Therapeutics aims to create cancer immunotherapy by irradiating and engineering existing cancer cells. Lead candidate Bria-IMT for breast cancer showed good tolerability and efficacy in 46 heavily pretreated patients so far.

BriaCell Therapeutics: Fast-Tracking High-Potential Breast Cancer Immunotherapy

PHILADELPHIA and VANCOUVER, British Columbia, Jan. 24, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, today issues a letter to shareholders from Dr. William V. Williams, BriaCell's President and CEO.

BriaCell CEO Letter to Shareholders

PHILADELPHIA and VANCOUVER, British Columbia, Jan. 23, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, announced today that it has approved measures to address alleged illegal trading activity of its publicly traded securities. The Company believes that certain individuals and/or companies may have engaged in manipulative and/or suspected illegal trading practices that may have artificially depressed its share price. As a result, BriaCell is implementing a plan to address this issue which may include legal action.

BriaCell to Investigate Alleged Illegal Trading of Public Securities

PHILADELPHIA and VANCOUVER, British Columbia,, Jan. 18, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is pleased to announce that it has received agreement and positive feedback from its End of Phase II meeting with the FDA regarding BriaCell's lead clinical candidate, Bria-IMT™ in combination with a checkpoint inhibitor (under Fast Track designation), in advanced metastatic breast cancer.

BriaCell Announces Positive End of Phase II Meeting with the FDA for Bria-IMT™ Combination in Advanced Metastatic Breast Cancer

PHILADELPHIA and VANCOUVER, British Columbia, Jan. 10, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is pleased to announce that it has received an Issue Notification from the United States Patent and Trademark Office for the composition of matter and method of use of its personalized off-the-shelf cell-based immunotherapy for cancer. The patent will issue on January 24, 2023 as US Patent No. 11,559,574 with the term extending to May 25, 2040. Additionally, BriaCell was awarded an Australian patent (Patent No. 2017224232, extends to February 27, 2037) covering composition of matter and method of use for its whole-cell cancer immunotherapy technology in Australia.

BriaCell Announces New Patent Issuance, Bria-OTS™ IND Timing Guidance, and Additional Clinical Sites to Boost Enrolment

PHILADELPHIA and VANCOUVER, British Columbia, Dec. 08, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, presented positive safety/tolerability and efficacy data from its lead product candidate, Bria-IMT™, summarized in three poster sessions during the 2022 San Antonio Breast Cancer Symposium® (SABCS).

BriaCell Announces Positive Clinical and Quality of Life Data in Advanced Metastatic Breast Cancer at 2022 San Antonio Breast Cancer Symposium®

Immunoprecise Antibodies Ltd

VICTORIA, British Columbia & VANCOUVER, British Columbia & PHILADELPHIA--( BUSINESS WIRE )--IPA (IMMUNOPRECISE ANTIBODIES LTD.) ( “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today announced that BioStrand BV (“BioStrand”), an AI in silico discovery subsidiary of IPA, has entered into a research collaboration and license agreement (the “Agreement”) with BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) (“BriaCell”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer.

IPA's Subsidiary BioStrand and BriaCell Announce Artificial Intelligence Collaboration and License Agreement to Discover and Develop Anti-Cancer Antibodies

PHILADELPHIA and VANCOUVER, British Columbia, Nov. 10, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is pleased to announce positive initial efficacy data in its 2021-2022 cohort of 12 advanced breast cancer patients. Disease control, tumor shrinkage, and potential survival benefit were observed amongst 12 patients in the Phase I/IIa clinical study of Bria-IMT™ in combination with Incyte's retifanlimab.

News for BriaCell Therapeutics Stock (BCTX)